

- 2 | 3° OTC INTERNATIONAL WORKSHOP
- 4 | THE ITALIAN SOCIETY OF PEDIATRIC ALLERGOLOGY AND IMMUNOLOGY
- 5 | IX INTERNATIONAL REGULATORY AFFAIRS MEETING

Product portfolio development

SALES +13,1%

THE FIRST QUARTER 2017 EXCELLENT RESULTS, CONTINUED GROWTH

CONSOLIDATED REVENUES in the first quarter 2017 are € 341.9 million, up by 13.1% compared to the same period of the preceding year. international sales grow by 11.2%.

EBITDA, at 34.4% of sales, is € 117.7 million, an increase of 18.9% over the same period of the preceding year.


OPERATING INCOME, at 31.4% of sales, is € 107.3 million, an increase of 19%.

NET INCOME, at 23% of sales, is € 78.5 million, an increase of 19.9% over the first quarter of 2016.

NET FINANCIAL POSITION at 31 March 2017 records a net debt of € 105.6 million compared to net debt of € 198.8 million at 31 December 2016.

SHAREHOLDERS' EQUITY increases to € 996.7 million.

As already announced in the 2017-2019 Business Plan, the Recordati Group signed important exclusive agreements from May to July which strengthened its product portfolio.



On July 3rd Recordati announced the successful conclusion of the agreement with **AstraZeneca** for the acquisition of the rights to **Seloken®/Seloken® ZOK** (metoprolol succinate) and associated **Logimax®** fixed dose combination (metoprolol succinate and felodipine) treatments in Europe. **Metoprolol succinate** is a beta-blocker for the control of hypertension, angina and heart failure. The consideration for the acquisition of the assets of \$ 290 million (€ 258 million) was paid at the closing. Overall net sales in Europe in 2016 of the brands object of the transaction are of around € 100 million. "We are very pleased with the agreement that we have entered into with AstraZeneca for the rights to their brands of metoprolol in Europe" stated Andrea Recordati, Vice Chairman and CEO. "Metoprolol is a widely used drug in all European countries and the market position achieved by the AstraZeneca brands will enable us to reinforce our product portfolios in a number of our European subsidiaries, in particular in Poland, France and Germany. Furthermore, existing sales of the metoprolol brands will provide the base to enter new markets and thus complete our European geographical footprint. Recordati has significant experience in the marketing of treatments for cardiovascular disease with an existing portfolio of medicines for hypertension and related conditions as well as an established salesforce across European markets. This new significant addition to our portfolio will strengthen our position in the European market and contribute to a further enhancement of our profitability margins".



On June 16th Recordati announced the signing of an exclusive license agreement with **MimeTech**, an Italian development stage company founded by scientists from the University in Florence, for the development and subsequent commercialization on a global basis of a low molecular weight peptidomimetic of human nerve growth factor (NGF) for **the treatment of neurotrophic keratitis**, which already received an Orphan Drug Designation in the EU. Additional indications linked to

NGF defects are also contemplated in the scope of the partnership. Neurotrophic keratitis is a rare degenerative corneal disease which in its more severe forms affects less than one person out of 10,000 worldwide, and is initiated by an impairment of trigeminal nerve. The most common causes of loss of corneal innervation are: viral infection (herpes simplex and herpes zoster keratoconjunctivitis), chemical burns, physical injuries, and corneal surgery. "This agreement allows us to further enhance our pipeline of products for the treatment of severe rare conditions", declared Andrea Recordati. "We continue to be committed to finding innovative solutions for unmet medical needs of patients suffering from severe disabling diseases."

"The financial results obtained in the first quarter of the year testify to the continued growth of the group also in 2017, with revenues and profitability increasing significantly", declared Andrea Recordati, Vice Chairman and CEO. "The group's business continued to perform very well during April and for the full year 2017 we are increasing our objectives and expect to achieve sales of around € 1,250 million, EBITDA of around € 425 million, EBIT of around € 380 million and net income of around € 275 million."

3° OTC International Workshop

MILAN, 18TH-19TH MAY

The OTC business, which is an important asset for Recordati, is showing good growth prospects, partly as a result of strong support from Corporate Marketing and synergies created between Group subsidiaries. The objective of the Third OTC International Workshop is to firmly consolidate the OTC team and growth in the sector through:

- better knowledge of corporate dynamics and getting to know colleagues in different subsidiaries
- sharing experiences in order to create sound synergies for projects and common activities
- a more in-depth culture of OTC in the Group.

Forty managers working in the OTC sector from 18 different countries took part in the workshop, flanked by the International Sales Team and by Italian managers, which confirmed the growing interest in the OTC sector, considered a priority for the future development of the Group in coming years. **Mauro Carbone** together with **Elisabetta Caruso** (OTC Team Corporate Marketing) provided very lively co-ordination of all the activities on a very tight agenda that had been set. This made it possible to examine many subjects, including projects implemented by subsidiaries and those presented by outside speakers.



In “**OTC Strategic for Recordati**”, **Miguel Isla** from the International Primary and Specialty Care Business Unit, underlined the growing importance of OTC business in the Recordati product portfolio, one of the most rapidly developing sectors for the Group. Isla also underlined that the path to the consolidation of organic growth is one that requires an integrated marketing approach and the activation and involvement of the various stakeholders (doctors, pharmacists and public), compatibly with the specifics of each individual subsidiary.

Francesco Soletti, Head of Corporate Marketing and Sales Force Effective-

ness, described the current dynamics of the OTC market, which has greater growth potential than other pharma sectors, and its future development. He especially highlighted key growth factors for OTC products and the converging interest in that market on the part of the pharmaceutical industry, mass retailers and the “global disruptors” (Apple, Amazon, Google). Ageing populations in Western countries, the greater attention paid to health, widespread use of digital technologies and apps on mobiles all demonstrate that consumer interest is focused on prevention and well-being as well as curative medicine.

In “**Evolution and Key dynamics of OTC Business across Recordati**” **Mauro Carbone**, the OTC Corporate Marketing Manager, presented the positive sales results for 2016 and the first quarter of 2017 (+19%), achieved primarily by the good performance of the excellent corporate brands (the “Top Brands”), which benefited greatly from strong marketing support and synergies created between branches. **Procto-Glyvenol®**, now the most important product with the fastest growth rate of all OTC products, is a concrete example of the success achieved as a result of co-ordinated activities and shared marketing strategies: one of the television commercials was actually selected among the finalists for an important European award. Mauro Carbone then emphasised the need to apply that same strategy to other brands in order to increase sales performance and conquer further leadership positions (out of 25 corporate products, 47% is considered “Top Brand”), or co-leadership

positions that the Group already holds in various markets.

In “**Exploiting RX+OTC synergies towards Sell Out**” **Michael Cristino**, Corporate Sales Force Effectiveness Manager, suggested various strategies to leverage the sales force to the maximum and to increase sell-out. He then illustrated various projects implemented by subsidiaries, again underlining the importance of capitalising on synergies that can be created between the speciality pharmaceutical and the OTC sales forces.



BARBARA KOHLER FROM RECORDATI PHARMA, WINNER OF THE “BEST CASE HISTORY” FOR RHINOPRONT®

The first day was dedicated to ways of bringing the major stakeholders, the public, pharmacists, sales outlets and doctors, into play. Sixteen projects were presented one after the other, in a lively manner and at a very fast pace, all examples of concrete success achieved by subsidiaries, models of inspiration to either follow or adapt to different national contexts. Everyone voted for the best project, the “**Best Case History**”. The first prize was won by Recordati Pharma for **Rhinopront®**, a nasal decongestant. The strategy pursued in Germany was brilliant: **Barbara**

Kolher explained how to maximise the return on an investment in advertising by using a carefully targeted and selective radio campaign. Romania also won a place on the podium with **Madalina Nitulescu**, for the very original launch of **CasenFibra®**, by using a successful awareness campaign. For Spain, **Helena Coll Hernán** told us how Casen Recordati had achieved greater visibility and sales success thanks to a digital strategy applied for the creation of a new integrated portal dedicated to a female public (**Me encuentro bien, Yo soy mujer**).

On the second day attention focused on corporate projects. The morning was taken up by the new **Corporate Media Agency Project**, sponsored by the Corporate Marketing and Group Purchasing teams, which involves improving the quality and efficiency of media services across the Group, by developing the partnership with this global media player. Mauro Carbone and Elisabetta Caruso illustrated the promising qualitative and quantitative results achieved thanks to collaboration with MEC – Corporate Media Agency, which made it possible to maximise returns on media investments and showed the importance of a common and shared approach by the various teams working in the OTC sector.



MADALINA NITULESCU FOR CASENFIBRA®

Andrea Fabrizio from the MEC Media Agency then illustrated how to implement integration between conventional media and digital media and described the guidelines for future media plans.

In the afternoon, after **Francesca Battezzati**'s presentation entitled "**More than 90 years of History**" on how the graphics of Recordati's brands and advertising has evolved, attention again turned to Mauro Carbone who explained the role of innovation for



From the left: ELISABETTA CARUSO BETWEEN PEDRO JOSÉ VARONA DIAZ AND ELENA COLL HERNÁN FROM CASEN RECORDATI AND MAURO CARBONE

the future of the OTC business. Mauro Carbone, illustrated the following: the **OTC business**, the results obtained from co-operation with the media agency MEC, the new trends for OTC business, the winning strategic implications for the Group such as the extensions of successful brands into adjacent market segments, the integration of the OTC product portfolio in the subsidiaries and the spread of local brands across different subsidiaries as corporate products.

At the end of the day **Ida Caramazza**, Head of Corporate Regulatory Affairs, presented "**Claims for healthcare products, a regulatory perspective**", explaining the important role of claims for healthcare products (pharmaceutical products, dietary supplements,

cosmetics) and the key differences in the Regulatory Affairs.

The "**Best Recordati Local Ad Award**" was also presented during the afternoon. The projects of the ten teams from subsidiaries were judged by the participants and the indisputable winner was the **Casen Recordati** Spanish team with a very creative TV video created for Reuteri Gotas®. Two projects by **Jaba Recordati** for the products Transact Lat® (an anti-inflammatory patch) and Guronsan® (an energiser for fatigue) also received most votes. Feedback on the workshop was unanimous in its positive appreciation of it. And despite the huge amount of work done, the participants were still happily surprised to take part in a lesson on Italian cuisine.



CHOOSE THE RIGHT INGREDIENTS, KNOW JUST HOW TO MIX THEM AND WHEN TO ADD A TOUCH OF SOMETHING SPECIAL, THAT'S THE RECIPE FOR A GREAT TEAM! THE WHOLE OTC TEAM TOOK PART IN AN EVENING LESSON ON ITALIAN CUISINE

The Italian Society of Pediatric Allergology and immunology

FLORENCE, 4TH-6TH MAY



The 19th National Congress of the Società Italiana di Allergologia e Immunologia Pediatrica (SIAIP – Italian Society for paediatric allergology and immunology), one of


the most important congresses, brought together around 600 paediatricians in Florence between 4th and 6th May.

Following its acquisition of Italchimici, the Recordati Group took part in the Congress for the first time with a large stand, a delegation of 47 paediatricians from all over Italy and a symposium entitled “**How the allergic response can be modified**”, focused on the characteristics of Reuflor® combined with the vitamin D3. The scientific committee, composed of professors **Diego Peroni** (Pisa), **Antonino Musarra** (Reggio Calabria) and Dr. **Roberto Bernardini** (Empoli), co-ordinated the symposium, which was attended by approximately 300 doctors. The speakers explained the properties of Reuflor®D3, a dietary supplement with a *Lactobacillus reuteri* DSM 17938 base and vitamin D3. *Lactobacillus reuteri* is a live and active lactic ferment with a probiotic action that helps to balance the bacterial flora in the intestines.

Professor **Atilio Boner** (Verona) illustrated the properties of vitamin D and Professor **Oliviero Rossi** (Florence) analysed the role of probiotics on the allergic response, while Professor **Michele Miraglia del Giudice** (Naples) presented “**From knowing to know-how**”, the main theme of this Congress. The following conclusions emerged from the symposium:

1. as reported by the World Allergy Organisation (WAO 2015), probiotics are able to stimulate immune defences and Reuflor® in particular has also demonstrated that it can reduce bronchial inflammation in asthmatic children;
2. confirmation that vitamin D3, when combined with probiotics in particular, is able to modulate the immune response helping both the normal function of the immune system and immune stimulation, naturally for the various forms of allergies (rhinitis, eczema).

To conclude, it is important to supplement the diet of all atopic/allergic children with Reuflor®D3, independently of the type of nursing, breastfeeding or bottlefeeding, because of the combined action of *Lactobacillus reuteri* DSM 17938 and vitamin D3.



THE STAND FOR REUFLOR® OF ITALCHIMICI IN FLORENCE



from the left: ANTONINO MUSARRA, ROBERTO BERNARDINI AND DIEGO PERONI

INDUSTRIA FELIX AWARD MILAN, 19TH MAY



THE CHAIRMAN ALBERTO RECORDATI RECEIVING THE PRIZE

The first edition of the “**Industria Felix Award - Lombardy that competes**” organised by the cultural association Industria Felix and sponsored by the LUISS Guido Carli University and the Lombard Confindustria (employers association) was held in Milan at the Assolombarda Auditorium on 19th May. This award originated from an investigation by the journalist Michele Montemurro: examples of excellence in Lombard businesses were selected on the basis of Cerved data, taken from the financial statements for the year 2015 of 31 thousand companies with registered office in Lombardy and sales turnover of between € 2 million and € 19.7 billion. Only fifty of these companies received the “Highest Honours”, reserved for best performances in their sectors or geographical areas, and “Balance sheet Mentions”, for those who were incontrovertibly the best in their province or region in terms of fundamental financial and operating indicators. **Recordati Industria Chimica e Farmaceutica** was recognised as the **best Lombard company in the chemicals and pharmaceuticals sector**.

European Association of Urology Congress

LONDON, 24TH-28TH MARCH

For the eighth consecutive year the Recordati Group took part in the EAU Congress held in London, the most important European urology congress, which brought together around 10,000 urologists from 118 countries.

The Recordati stand, which was in an excellent position and clearly visible, was positioned among the other stands of the main pharmaceutical companies in the urology field. In addition to a particularly exciting design, the floor space of 140 m² attracted the attention of doctors to the new led walls introduced in this edition to provide interactive scientific communication. Visitors could in fact interact with a big screen and choose the most interesting information from a list of items shown. This interactive system enabled doctors to ask specific questions and receive detailed replies, thereby avoiding the danger of receiving only generic information. Three products were presented to the Urology community using animated pictures and videos: **Urorec®**, **Vitaros®** and, for the first time, **Fortacin®**. The first two pharmaceuticals were the focus of the **"Meet the Expert"** sessions, always well attended. All the activities were co-ordinated with the aim of providing well articulated and exhaustive information by our KOLs in the different symposia. The symposium entitled **"BPH and obstructive uropathy: role of alpha-blockers"** presided by Professor **F. Montorsi**. Professors **V.G. Mirone** (Naples, Italy) and **H. Lepor** (New York, USA) provided an excellent illustration of the role of alpha-blockers to alleviate the symptoms of obstruction due to benign prostatic hyperplasia (BPH) and the characteristics of silodosin (Urorec®) in particular. Professor **H. Porst** (Hamburg, Germany) presided over the symposium entitled **"Novelty in Premature Ejaculation"**, while Professor **F. Giuliano** (Garches, France) illustrated the clinical profile of Fortacin® and Professor **P.S. Kirana** (Thessalonica, Greece), a famed psychologist, explained the psychological aspects of male sexual disorders to the neurologist and sexologists present.



RECORDATI IN CANADA FOR RARE DISEASES

On April 13th, Recordati, a global biopharmaceutical company committed to providing orphan therapies to underserved rare disease communities, announced the incorporation of its Canadian affiliate, Recordati Rare Diseases Canada Inc.

Recordati Rare Diseases Canada, a company wholly owned by the Italy-based Recordati Group, will be the exclusive provider of several treatments, including Carbaglu® (carglumic acid), Cystadane® (betaine anhydrous) and Cosmegen® (dactinomycin) in Canada.

"We're thrilled to be a part of Canada's innovative biopharmaceutical community focused on bringing treatments to ultra-rare disease and oncology patients" said **Paul McCabe**, Vice President and General Manager, Recordati Rare Diseases Canada. *"As a company, we're happy to be able to bring these products together under one umbrella to offer the highest-quality treatments to these patients."*

Based in Toronto, Recordati has launched a new website designed to assist Canadians with certain rare diseases across the country. For more information, visit www.recordatirarediseases.ca.



From left to right: PAUL MCCABE, CORRADO CASTELLUCCI, ANDREA KISTNER AND MICHAEL WATERS

CARIPRAZINE

On 19th May the EU pharmaceutical agency (the Committee for Medicinal Products for Human Use – CHMP) recommended the approval of cariprazine for schizophrenia in adult patients.

In August 2016 the Recordati Group signed an exclusive agreement to market cariprazine in Western Europe, Algeria, Tunisia and Turkey.

The inclusion of cariprazine (Reagila®) in its product portfolio opens up a new treatment area for group, that of neurological disorders.

IX International Regulatory Affairs Meeting

MILAN, 12TH-13TH APRIL

Those attending the 9th **International Regulatory Affairs Meeting (IRAM)** held in Milan on 12th April in Via Marostica and at headquarters on the following day experienced two days of very hard work.

This year 47 people took part: 27 managers from different subsidiaries and 20 staff from Regulatory Affairs or Production at the Milan headquarters.

On the morning of the first day **Ida Camarazza**, Head of Group Regulatory Affairs, addressed issues concerning the work and responsibilities of pharmacovigilance and Regulatory Affairs. The time spent on corporate products was divided into a full four working sessions, a commitment that indicates the strategic importance of this sector for the Group. The regulatory updates needed for the transition of some local

products were analysed. These are currently sold successfully in one country only and will be marketed at corporate level on various markets, a transition planned under the OTC corporate portfolio project (see page 3).

Following the session on corporate active pharmaceutical ingredients and on the innovative **"Wings for the future: serialisation project"**, 20 participants were welcomed to the **production department in Via Civitali** for a guided visit. Here they were able to see the various production stages ranging from water sterilisation, to processing of the active ingredients and the final packaging of the pharmaceuticals in tablet, phial or ointment form. The day then ended with a visit to the Porta Nuova District, the area of Milan in which skyscrapers designed by famous architects stand.

The second day was dedicated to instruments and the organisation of the challenges launched by Regulatory Affairs: various workshops were organised on technical subjects such as the identification of medicinal products, the management of regulatory information and how information is filed.

The final part of the meeting focused on the corporate products Fortacin®, cariprazine and fenticonazole.



A VISIT WAS ORGANISED TO THE PORTA NUOVA DISTRICT



4TH CITRAFLEET SCIENTIFIC SESSIONS MADRID, 5TH JUNE



The **International Department of Casen Recordati**, the Recordati Group's Spanish subsidiary, organised the fourth Citrafleet Scientific Sessions, inviting leading experts in gastroenterology and endoscopy from ten different countries. The objectives of the meeting were: to share the best practises and clinical approaches, to illustrate updates on diagnosis procedures in order to improve the quality of colonoscopy according to the latest clinical recommendations, to achieve an accurate diagnosis and to provide participants with an overall vision for **the prevention in colorectal cancer**. The professors who spoke were: Ignacio Fernández-Urién, Navarra Hospital Complex, Rodrigo Jover, General Hospital of Alicante, Jean-Christophe Saurin, Edouard Herriot Hospital of Lyon, France, Pedro Boal Carvalho, Senhora da Oliveira Hospital, Portugal and Dra. María Pellisé, Clinic Hospital at Barcelona, Dra. Monika Ferlitsch, Medical University of Vienna.

Cardio Master Class


4TH MASTER CLASS ON MICROCIRCULATION

ATHENS, 6TH-7TH MARCH

In view of the success enjoyed by the previous three editions, it was decided to hold another **Master Class on Microcirculation** on the 6th and 7th March in Athens. This practical and theoretical course was attended by 46 doctors specialising in cardiology, nephrology, internal medicine and endocrinology. The course focused, under the scientific direction of Professor **Konstantinos Tsioufis**, assisted by professors **Kyriako Dimitriadis** (Greece), **Giuseppe Mancica** and **Damiano Rizzoni** (Italy), on the importance of microcirculation and on the key role that this complex system of small blood vessels plays in many aspects of physiology and pathology. It is widely recognised that high blood pressure can progressively deteriorate the functions of the capillaries through

anatomical changes. This is particularly evident in target organs such as the brain, heart and kidneys. The micro vessels damage are often greater in diabetic patients for whom vascular damage is already present as a consequence of their defective metabolic condition. During the day, after first learning the basic concepts of the role of microcirculation as a new parameter for the assessment of cardiovascular risk, the doctors carried out a practical exercise on the use of instruments to measure a particularly problematic hypertensive patient. The advantages of a fixed combination of lercanidipine/enalapril especially for elderly, diabetic and kidney disorder patients with organ damage were then illustrated to the participants on the course. On the second day the

doctors visited a cardiology centre at the Hippokration Hospital in Athens, to see a live capillaroscopy examination performed by Professor Tsioufis. As a result of the high scientific level of the theoretical contents and the practical activities, the participants received a certificate and 8 CME credits.



2ND MASTER CLASS OF ARTERIAL STIFFNESS

DUBROVNIK, 3TH-5TH APRIL


The second "**Master Class of Arterial Stiffness**" was held in Dubrovnik from 3rd to 5th April organised by Recordati in co-operation with the Istituto Auxologico Italiano (Italian Auxological Institute) and the Società Italiana dell'Iperensione Arteriosa (SIIA – Italian Hypertension Society). This theoretical and practical course was co-ordinated by a scientific committee composed of professors **Bojan Jelakovic** (Croatia) and **Paolo Salvi** (Istituto Auxologico Italiano, Milan) and it was directed by Professor **Gianfranco Parati**, the Director of the cardio-neuro-metabolic Department of the San Luca Hospital of Milan University. During the course the doctors learnt essential theoretical concepts for the assessment of arterial stiffness and its role in organ damage in patients with essential arterial hypertension. They then took part in practical exercises as they learnt to use instruments to measure it. The accent was placed on the role of

the aorta and the large elastic arteries in the haemodynamic vascular system, on the measurement of arterial pressure and on the assessment of arterial stiffness by measuring the carotid-femoral pulse wave velocity (aortic Pulse Wave Velocity, PWV).

It is in fact well known that arterial stiffness is an independent risk factor in hypertensive patients. Since this parameter can be modified by using optimal antihypertensive therapies, better knowledge of how to measure arterial stiffness and its characteristics could help doctors to improve antihypertensive therapies in daily clinical practice.

Details were given at the end of the course on the effectiveness of the lercanidipine/enalapril fixed combination to control hypertension. At the end of the workshop the 46 participants (cardiologists, nephrologists and specialists in internal medicine) also took an exam to obtain certification of the Italian Au-

xological Institute. The high standards of the scientific contents and the practical exercises were judged positively by the participants who received 14 EBAC credits.



Italian Business Oscar goes to Opalia Pharma

TUNIS, 22ND APRIL

The Italian ambassador to Tunis and the Italian-Tunisian Chamber of Commerce organised the first edition of the Italian Business Oscar which was awarded to Opalia Pharma, the group's tunisian subsidiary. The award-giving ceremony took place on 22nd April during a gala dinner held at the Cigale Tabarka Hotel, which brought together businessmen and representatives of institutions who have worked to increase trade, investment and economic relations between Italy and Tunisia.

Opalia Pharma won the first prize for investment. The Tunisian subsidiary, acquired by the Recordati Group in 2013 and led by Mme Alya El Hedda, is the leading exporter of pharmaceuticals and holds the fourth position for national production. The number one company in the generic pharmaceuticals sector, it has a large specialty drug portfolio ranging from paediatrics, cardiology and neurology to urology and nephrology.



MME ALYA EL HEDDA RECEIVES THE OSCAR WON BY OPALIA PHARMA AS ITALIAN BEST INVESTOR IN TUNISIA

ALBERTO RECORDATI THANKS MARIA MONASTERO AND ELENA POGGESI



MARIA MONASTERO AND ELENA POGGESI'S HARD WORK CONSTITUTES A TOTAL OF 70 YEARS DEDICATED TO THE COMPANY

The Chairman, Alberto Recordati, wished to congratulate and personally thank these two such memorable workers in the company: Maria Monastero and Elena Poggesi. Mrs Maria Monastero had worked in the company for 41 years and went into retirement on 31st March. Mrs Monastero, who is originally from Siacca, was first appointed on a temporary contract to replace a worker in the production department on maternity

leave. That contract was then converted to a permanent position on 10th November 1976. Over the last 10 years Mrs Monastero has been employed on the production line, working on printing and checking production documentation.

On 31st May the Chairman met and thanked *dottressa* Elena Poggesi, who left the company to go into retirement after 29 years of dedication to the company. *Dottressa* Elena Poggesi, born in Bologna on 22nd August 1952, with an honours degree in biological sciences, *dottressa* Elena Poggesi, joined Recordati on 18th April 1988 as a Senior Research officer in the Toxicology Pharma Research Section. She then went on, within that section, to gain responsibility for the General Pharmacological Laboratory (in vitro).

ANTOINE GROUES



Antoine Groues left the Recordati Group on the 9th June after 10 years with the company. Born on 14th October 1975, with a

degree in biology, having acquired experience in the pharmaceutical field he joined Recordati in 2007 as Export Manager for the company Bouchara Recordati.

In June 2010 he was placed in charge of the International Pharmaceutical Sales Business and then became General Manager of Recordati Ireland Ltd in November 2012. Antoine was saluted by his Irish colleagues who presented him with a shirt of the team of his heart, the Cork Football Team.